Cannabinoids and endocannabinoids as therapeutics for nervous system disorders:preclinical models and clinical studies

被引：0
|
作者：
R.Scott Duncan [1 ]
Sean M.Riordan [1 ]
Matthew C.Gernon [1 ]
Peter Koulen [1 ,2 ]
机构：
[1] Department of Ophthalmology, School of Medicine, University of Missouri
[2] Department of Biomedical Sciences, School of Medicine, University of Missouri
来源：
Neural Regeneration Research | 2024年 / 19卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R741 [神经病学];
学科分类号：
1002 ;
摘要：
Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system(CNS) diseases and dysfunctions such as forms of epilepsy, multiple sclerosis, Parkinson’s disease, pain and neuropsychiatric disorders. In addition, the endogenously produced cannabinoid lipids, endocannabinoids, are critical for normal CNS function, and if controlled or modified, may represent an additional therapeutic avenue for CNS diseases. This review discusses in vitro cellular, ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS pathologies. In addition, the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS diseases. Cannabinoids and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders.
引用
收藏
页码：788 / 799
页数：12
相关论文
共 50 条
  • [21] Pharmacological Actions of Myricetin in the Nervous System: A Comprehensive Review of Preclinical Studies in Animals and Cell Models
    Li, Jie
    Xiang, Haitao
    Huang, Chao
    Lu, Jiashu
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [22] Improving animal models for nervous system disorders
    Brown, R. E.
    GENES BRAIN AND BEHAVIOR, 2012, 11 (06) : 753 - 756
  • [23] Neuroimmunophilin ligands as novel therapeutics for the treatment of degenerative disorders of the nervous system
    Hamilton, GS
    Steiner, JP
    CURRENT PHARMACEUTICAL DESIGN, 1997, 3 (04) : 405 - 428
  • [24] Sympathetic nervous system activation and its consequences following subarachnoid bleeding:: Clinical and preclinical studies
    Lambert, G
    Naredi, S
    Zäll, Z
    Rydenhag, B
    Gaudet, E
    Elghozi, JL
    Friberg, P
    JOURNAL OF HYPERTENSION, 1998, 16 : S175 - S175
  • [25] Role of Preclinical Arthritis Models for the Clinical Translation of Anti- Arthritic Therapeutics
    Singha, L. Ronibala
    Das, Malay K.
    PHARMACEUTICAL SCIENCES, 2023, 29 (03) : 263 - 282
  • [26] Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System
    Julius Gene S. Latorre
    Elena B. Schmidt
    Current Cardiology Reports, 2015, 17
  • [27] Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System
    Latorre, Julius Gene S.
    Schmidt, Elena B.
    CURRENT CARDIOLOGY REPORTS, 2015, 17 (09)
  • [28] Hereditary disorders of the nervous system - From anatomo-clinical studies to molecular biology
    Martin, JJ
    ACTA NEUROLOGICA BELGICA, 1996, 96 (03) : 240 - 246
  • [29] Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System
    Gao, Huile
    Pang, Zhiqing
    Jiang, Xinguo
    PHARMACEUTICAL RESEARCH, 2013, 30 (10) : 2485 - 2498
  • [30] Nucleic acid-based therapeutics for the treatment of central nervous system disorders
    Mccartan, Robyn
    Khorkova, Olga
    Volmar, Claude-Henry
    Wahlestedt, Claes
    FRONTIERS IN GENETICS, 2023, 14
12345